Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1105315

registered interest
date	26/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cervical Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of people being able to self-refer for a smear test in a local sexual health clinic.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	237191
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>The United Kingdom National Screening Committee has made no assessment of the evidence to offer self-referral as part of the National Health Service cervical screening programme. The programme is working with contraception and sexual health clinics to support women who attend for their routine cervical screening, which is offered by some local authorities.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 15:40:52 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1104692

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many oncology patients have been registered to receive treatment through the NHS in each year since 2010.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	236365
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236367 236369 question first answered 02/04/2019 11:24:26 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1104693

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Professions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many (a) nurses and (b) doctors are specifically employed within the oncology speciality.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	236366
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS Digital publishes Hospital and Community Health Services workforce statistics. These include staff working in hospital trusts and clinical commissioning groups, but not staff working in primary care, local authorities or other providers.</p><p> </p><p>The latest NHS Digital workforce statistics show that as at 30 December 2018 there are 1,317 doctors with a speciality in clinical oncology and 985 doctors with a speciality in medical oncology. The figures include all doctors working in the specialty of oncology such as consultants, associate specialists, specialty doctors, doctors in training etc.</p><p> </p><p>The latest NHS Digital workforce statistics show that as at 30 December 2018 there are 2,093 nurses who work in an area of ‘clinical oncology’ and 1,237 nurses who work in an area of ‘medical oncology’. This data represents nurses who are working in services related to oncology, rather than nurses with specialist training in oncology.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 11:43:26 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1104694

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much the NHS spent on providing oncological treatment in each year since 2010.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	236367
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236365 236369 question first answered 02/04/2019 11:24:27 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1104696

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many IT systems are used within oncological treatment in the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	236369
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236365 236367 question first answered 02/04/2019 11:24:27 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1104708

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether NHS England plans to continue to fund the NICE commissioning support programme until the capacity of the NICE appraisal programme is increased to enable the routine assessment of all new medicines.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	236380
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS England is continuing the commissioning support work programme in 2019/20, with the expectation that the National Institute for Health and Care Excellence will have extended its capacity by 2020.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 11:44:12 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1104709

registered interest
date	25/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Priorities Advisory Group
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which clinical policies awaiting review by the Clinical Priorities Advisory Group involve the use of the NICE commissioning support programme.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	236381
answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>The clinical policies awaiting review by the Clinical Priorities Advisory Group, which involve the use of the National Institute for Health and Care Excellence (NICE) commissioning support work programme are as follows:</p><p>- Chenodeoxycholic acid and cholic acid for treating inborn errors in primary bile acid synthesis;</p><p>- Telotristat for treating carcinoid syndrome;</p><p>- Bictegravir-emtricitabine-tenofovir alafenamide for treating HIV-1;</p><p>- Idebenone for treating Leber hereditary optic neuropathy;</p><p>- Canakinumab for treating periodic fever syndromes;</p><p>- Emicizumab for bleed prevention in severe and moderate haemophilia A without inhibitors;</p><p>- Dolutegravir with rilpivirine for treating HIV in people with viral suppression;</p><p>- Doravirine for treating HIV infection;</p><p>- Vonicog alfa for the treatment of bleeding in adults with von Willebrand disease; and</p><p>- Mercaptamine hydrochloride for treating corneal cystine crystal deposits caused by cystinosis.</p><p>NICE’s work on Ivacaftor for treating cystic fibrosis with a R117H mutation in the CFTR gene is currently paused.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 11:41:45 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1091200

registered interest
date	19/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Negligence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the potential cost of clinical negligence claims to NHS Resolution over the next three years.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	234131
answer	answer is ministerial correction date of answer 27/03/2019 answer text <p>NHS Resolution handles clinical negligence claims on behalf of National Health Service organisations and independent sector providers of NHS care in England.</p><p> </p><p>NHS Resolution have provided the following information which covers spend specifically attributed to clinical negligence, principally pay-outs pertaining to claims received under the Clinical Negligence Scheme for Trusts. The figures also include clinical negligence pay-outs relating to Department-funded indemnity schemes in respect of legacy bodies such as primary care trusts and regional health authorities.</p><p> </p><p>Costs in the context of HM Treasury-defined budgeting arrangements are defined as the amount expected to be paid in relation to settling claims in that financial year, including damages payments, claimant legal costs, and defence legal costs, and are shown in the following table.</p><p> </p><p>The costs reported do not include NHS Resolution administration or costs incurred locally by NHS providers in dealing with claims such as their own administration costs.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Clinical Negligence Scheme for Trusts (£ million)</p></td><td><p>Department of Health Scheme for Clinical Liabilities (£ million)</p></td><td><p>Existing Liabilities Scheme (£ million)</p></td><td><p>Regional Health Authorities Scheme (£ million)</p></td><td><p>Total (£ million)</p></td></tr><tr><td><p>2019/20</p></td><td><p>2,300</p></td><td><p>96</p></td><td><p>36</p></td><td><p>1</p></td><td><p>2,433</p></td></tr><tr><td><p>2020/21</p></td><td><p>2,410</p></td><td><p>90</p></td><td><p>35</p></td><td><p>1</p></td><td><p>2,536</p></td></tr><tr><td><p>2021/22</p></td><td><p>2,710</p></td><td><p>85</p></td><td><p>34</p></td><td><p>1</p></td><td><p>2,830</p></td></tr></tbody></table><p> </p><p>Notes:</p><p>The costs have been estimated on the basis of a personal injury discount rate (PIDR) of minus 0.75%. However, The Civil Liability Act 2018 includes a new way of setting the PIDR rate. A review of the PIDR rate has been announced and therefore the figures provided here may change.</p><p>NHS Resolution reviews its five-year forecasts annually and any changes in the underpinning actuarial assumptions are likely to result in revised projections. The figures quoted should therefore be considered as broad estimates based on latest available information and subject to change in the future.</p><p>The figures provided in this reply do not include claims brought against general practitioners.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 27/03/2019 12:46:00 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1091201

registered interest
date	19/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Negligence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Ministry of Justice and Civil Justice Council on reforming the tort of negligence in medical malpractice to address the rising cost of clinical negligence claims on NHS Resolution.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	234132
answer	answer is ministerial correction date of answer 27/03/2019 answer text <p>In 2017 the National Audit Office (NAO) published a report which challenged the Government to publish a co-ordinated strategy to reduce clinical negligence costs.</p><p> </p><p>The Department of Health and Social Care is working jointly with the Ministry of Justice, the Treasury, Cabinet Office, NHS Resolution and others, to respond to the challenge from the NAO in their ‘Managing the Costs of Clinical Negligence in Trusts’ report to publish a co-ordinated strategy to reduce clinical negligence costs. We are looking at all the drivers of costs, as challenged by the NAO, and a wide range of options are being considered. We will update the House when we are in a position to do so.</p><p> </p><p>The Civil Justice Council (CJC) is expected to report shortly on proposals to extend fixed recoverable costs (FRC) in clinical negligence cases up to £25,000 damages. The Government will consult before implementing any extension of FRC following the CJC report.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 27/03/2019 12:41:59 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1091207

registered interest
date	19/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the clinical rationale is to charge people with asthma for their prescription charges when people with many other long-term conditions are exempt from paying.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	234138
answer	answer is ministerial correction date of answer 27/03/2019 answer text <p>The Department has made no assessment on the effect of prescription charges on the young people with asthma and on the incidence of asthma attacks in England. The Department has made no estimate of the number of people with asthma who have missed their medication due to the cost of a prescription. Extensive arrangements are in place to help people afford NHS prescriptions. These include a broad range of prescription charge exemptions, for which someone with asthma may qualify.</p><p> </p><p>The Department has no current plans to amend these exemptions, including the list of medical conditions that provides exemption from prescription charges. Children under 16, and students under the age of 19 and in qualifying full-time education are also exempt from prescription charges. People on a low income, who do not qualify for an exemption, may be eligible for full or partial help with prescription charges through application to the NHS Low Income Scheme.</p><p> </p><p>To support those with greatest need who do not qualify for an exemption or the NHS Low Income Scheme, prescription prepayment certificates are available. A holder of a 12-month certificate can get all the prescriptions they need for just £2 per week.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 234139 234140 234141 question first answered 27/03/2019 12:44:24 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon